CU2 Stock Chart & Stats
€1.70
-€0.05(-3.35%)
At close: 4:00 PM EST
€1.70
-€0.05(-3.35%)
Day’s Range― - ―
52-Week Range€0.99 - €2.96
Previous CloseN/A
Volume200.00
Average Volume (3M)395.00
Market Cap
€516.07M
Enterprise Value€371.00
Total Cash (Recent Filing)€80.42M
Total Debt (Recent Filing)€97.36M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Jul 30, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding200,368,970
10 Day Avg. Volume0
30 Day Avg. Volume395
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.93Price Target Upside131.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€221.07M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueCerus's business model centers on INTERCEPT consumables that are required each treated unit, producing durable, repeatable revenue tied to blood center procedure volumes. This consumable attachment drives predictable unit economics, supports margin scalability as volumes grow, and underpins long-term revenue visibility.
Strong Product Growth And Raised GuidanceAccelerating product revenue and upward guidance reflect expanding commercial traction, especially in North America and EMEA. Sustained double-digit product growth supports recurring consumable demand, validates commercial execution, and increases the probability of durable revenue scale over the next 2–6 months.
Improving Balance Sheet LeverageMaterial debt reduction and stronger equity alleviate leverage-driven constraints, improving financial flexibility. Lower leverage reduces interest burden risk, widens strategic options for capital allocation, and enhances the firm's ability to fund regulatory launches and working-capital needs without destabilizing liquidity.
Bears Say
Ongoing UnprofitabilityDespite narrowing losses, Cerus remains unprofitable on a TTM basis, which constrains internal capital for R&D and commercialization. Persistent negative operating profit means the company remains dependent on external financing or cash reserves, limiting reinvestment flexibility and raising execution risk over the medium term.
Gross Margin HeadwindsSustained margin compression from inflation, shipping, tariffs and FX reduces earnings leverage from revenue growth. Lower gross margins pressure the pathway to GAAP profitability, force tighter cost control or price increases, and can erode returns on incremental volume over the next several quarters.
Regulatory & Rollout Timing RiskKey product milestones (RBC CE Mark, ANSM review, illuminator PMA timing) carry execution and timing uncertainty; delays could defer a major revenue stream. Early-stage IFC adoption is uneven, making revenue contributions lumpy and complicating forecasting and working-capital planning across quarters.
Cerus News
CU2 FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was €0.99 and its highest was €2.96 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is €516.07M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 4 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Apr 30, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.035 by €0.026.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 200,368,970 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.035. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in DE:CU2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.93 (131.38% Upside)
€3.93 (131.38% Upside)
Blogger Sentiment
Bullish
DE:CU2 Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €46.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CU2 Stock 12 Month Forecast
Average Price Target
€3.93
▲(131.38% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―